Multi-omics analysis reveals drivers of loss of β-cell function after 1

newly diagnosed autoimmune type 1 diabetes:

3

14

2

An INNODIA[‡] multicenter study

Jose Juan Almagro Armenteros, PhD^{1†}, Caroline Brorsson, PhD^{1†}, Christian Holm Johansen, 4

- 5 MSc^{1†}, Karina Banasik, PhD¹, Gianluca Mazzoni, PhD¹, Robert Moulder, PhD^{2,3}, Karoliina
- Hirvonen, MSc^{2,3}, Tomi Suomi, PhD^{2,3}, Omid Rasool, PhD^{2,3}, Sylvaine FA Bruggraber, 6
- PhD⁴, M Loredana Marcovecchio, MD⁴, Emile Hendricks, MD⁴, Naba Al-Sari, PhD⁵, Ismo 7
- 8 Mattila, MSc⁵, Cristina Legido-Quigley, PhD⁵, Tommi Suvitaival⁵, PhD, Piotr J Chmura, PhD¹, Mikael Knip, MD^{6,7}, Anke M Schulte, MD⁸, Jeong Heon Lee, PhD⁹, Guido Sebastiani, 9
- PhD^{10,11}, Giuseppina Emanuela Grieco, PhD^{10,11}, Laura L Elo, PhD^{2,3,12}, Simranjeet Kaur, 10
- PhD¹³, Flemming Pociot, MD¹³, Francesco Dotta, MD^{10,14}, Tim Tree, PhD¹⁵, Riitta 11
- Lahesmaa, MD^{2,3}, Lut Overbergh, PhD¹⁶, Chantal Mathieu, MD¹⁶, Mark Peakman, MD^{9,15}, 12
- Søren Brunak, PhD^{1*} on behalf of the INNODIA[‡] investigators 13
- 15 ¹Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical
- 16 Sciences, University of Copenhagen, Copenhagen, Denmark
- 17 ²Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
- ³InFLAMES Research Flagship Center, University of Turku, Turku Finland 18
- 19 ⁴Department of Paediatrics, University of Cambridge, Cambridge, England
- 20 ⁵Steno Diabetes Center Copenhagen, Systems Medicine, Herlev, Denmark
- 21 ⁶Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University
- 22 of Helsinki, Helsinki, Finland
- 23 ⁷Pediatric Research Center, New Children's Hospital, Helsinki University Hospital
- 24 ⁸Bayer Pharmaceuticals, Berlin, Germany
- 25 ⁹Immunology & Inflammation Research Therapeutic Area, Sanofi, MA, USA
- ¹⁰Department of Medicine, Surgery and Neuroscience, Università degli Studi di Siena, Siena, 26
- 27 Italy
- ¹¹ Fondazione Umberto di Mario, ONLUS Toscana Life Sciences, Siena, Italy 28
- 29 ¹²Institute of Biomedicine, University of Turku, Turku, Finland
- 30 ¹³Steno Diabetes Center Copenhagen, Herlev University Hospital, Region Hovedstaden,
- 31 Denmark
- 32 ¹⁴Tuscany Centre for Precision Medicine (CReMeP), Siena, Italy
- 33 ¹⁵Department of Immunobiology, King's College, London, UK
- 34 ¹⁶Department of Chronic Diseases and Metabolism, Endocrinology, Katholieke Universiteit
- INSTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 35

36

- 37 [†] Shared first author
- 38 * Corresponding author:
- 39 Søren Brunak, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and
- 40 Medical Sciences, University of Copenhagen, Blegdamsvej 3A, DK-2200 Copenhagen,
- 41 Denmark. Tel: +45-35325000, Email: soren.brunak@cpr.ku.dk.
- 42 ^{*}INNODIA: "Innovative approaches to understanding and arresting type 1 diabetes"- List
- 43 of contributors included with submission.

45 Abstract

46 Background

- 47 Heterogeneity in the rate of β -cell loss in newly diagnosed type 1 diabetes patients is poorly
- 48 understood and creates a barrier to designing and interpreting disease-modifying clinical
- 49 trials. Integrative analyses of complementary multi-omics data obtained after the diagnosis of
- 50 T1D may provide mechanistic insight into the diverse rates of disease progression.

51 Methods

- 52 We collected samples in a pan-European consortium that enabled the concerted analysis of
- 53 five different omics modalities in data from 97 newly diagnosed patients. In this study we
- 54 used Multi-Omics Factor Analysis to identify molecular signatures correlating with post-
- 55 diagnosis decline in β -cell mass measured as fasting C-peptide.

56 **Results**

- 57 Two molecular signatures were significantly correlated with fasting C-peptide levels. One
- 58 signature showed a correlation to neutrophil degranulation, cytokine signaling, lymphoid and
- 59 non-lymphoid cell interactions and G-protein coupled receptor signaling events that were
- 60 inversely associated with rapid decline in β -cell function. The second signature was related to
- 61 translation and viral infection were inversely associated with change in β-cell function. In
- 62 addition, the immunomics data revealed a Natural Killer cell signature associated with rapid
- 63 β -cell decline.

64 Conclusion

- 65 Features that differ between individuals with slow and rapid decline in β -cell mass could be
- valuable in staging and prediction of the rate of disease progression and thus enable smarter
- 67 (shorter and smaller) trial designs for disease modifying therapies, as well as offering
- 68 biomarkers of therapeutic effect.
- 69

70 Funding

- 71 This work is funded by the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU)
- vunder grant agreement N° 115797 (INNODIA) and N° 945268 (INNODIA HARVEST). This
- 73 Joint Undertaking receives support from the Union's Horizon 2020 research and innovation
- 74 program and 'EFPIA', 'JDRF' and 'The Leona M. and Harry B. Helmsley Charitable Trust'.
- 75

76 Introduction

77 Type 1 diabetes is an autoimmune disease involving environmental and genetic factors that 78 trigger immune-mediated pancreatic β-cell dysfunction and destruction that results in insulin 79 loss and symptomatic hyperglycemia requiring lifelong insulin therapy¹. Globally, around 1.2 80 million people below the age of 20 years have type 1 diabetes, with an annually increasing incidence of 3% influenced strongly by geography². Insulin replacement therapy is unable to 81 82 fully mimic physiological control of blood glucose and therefore, many people living with type 83 1 diabetes develop severe disease complications that are directly attributable to prolonged 84 glycemic exposure³, with markedly reduced life expectancy⁴. In the face of the disease burden and unmet need, international consortia are mobilizing to develop disease-modifying therapies. 85 For example, therapies that maintain even minimal residual C-peptide secretion capacity have 86 been found to have demonstrable clinical benefit⁵. An emerging barrier to this effort is disease 87 88 heterogeneity. In particular, the rate of decline of β -cell capacity is highly variable, for reasons 89 that remain unclear. As a result, clinical trial designs for disease-modifying therapies are 90 necessarily cumbersome, requiring large sample sizes and prolonged observation. In addition, 91 opportunities for tailored disease-modifying therapies are limited by an unclear understanding 92 of the factors that drive diabetes progression after diagnosis. Gaining this knowledge could 93 provide the attainment for improved participant inclusion in focused designed trials to foster 94 their success and participant benefit⁶.

95

Studies with this goal conducted to date have typically been constrained by limitations to cohort 96 97 size and the number of different data dimensions available for analysis^{7,8}. Thus, it has not been 98 possible to conduct studies with an emphasis on hypothesis-generating, unbiased approaches, 99 and integration of data across pathophysiological systems. These require large-scale, inter-100 disciplinary research efforts, in which carefully curated longitudinal clinical cohorts are aligned 101 with multi-parametric technology platforms. Such a systems-based approach can address key 102 questions with less bias and generate novel hypotheses on disease drivers. We used this strategy in the setting of a pan-European research consortium in which people with newly diagnosed 103 104 type 1 diabetes as well as people at risk of developing type 1 diabetes (antibody positive) were enrolled into a master protocol⁹ to conduct a prospective study in search of factors that correlate 105 106 with the rate of decline in β -cell mass/function. This endeavor was supported by the Innovative 107 Medicines Initiative-2 Joint Undertaking, where INNODIA was created, being a private-public 108 partnership of 40 partners in 16 countries. In the natural history study, people with newly 109 diagnosed type 1 diabetes and unaffected family members are in follow up, allowing deep

clinical characterization, as well as multi-omics analysis of samples (blood, urine, stool) collected and analyzed using standardized operating procedures (www.innodia.eu). Here we report the multi-omics analysis of the 'first 100' people with newly diagnosed disease. We report the existence of latent factors integrated from transcriptomic, small RNA, genomic, targeted proteomic, lipidomic, metabolomic, and immunomic-level data that show a relationship to subsequent rates of disease progression and have potential value as stratification

116 and therapeutic target identification tools.

117 **Results**

118 **C-peptide decline over time**

119 The individual rates of decline in C-peptide levels over time were calculated, defined as the 120 slope of C-peptide change over 12 months as described in Methods (Supplementary Fig. 1). 121 Two individuals only had one available C-peptide measurement and were not assigned a group 122 as C-peptide decline could not be determined. An overall trend of C-peptide decline over time 123 was observed for the entire cohort (p-value 0.0001) (Fig. 2A). By calculating the C-peptide 124 slopes using a linear mixed-effect model, the participants were divided into terciles (equal-125 sized), classified as rapid, slow, and increasing progression groups, yielding three groups with 126 distinct progression patterns (Fig. 2B). All three progression groups had a similar estimated 127 baseline C-peptide value (p-value 0.296), but significant C-peptide slopes (p-value < 0.0001). 128 The clinical features for each of the progression groups are shown in Table 1.

129

We further analyzed the relationship between age and C-peptide change over time (Fig. 2C) as 130 131 this was the only significant difference between the progression groups (Table 1). Participants 132 less than ten years old had a significantly lower baseline C-peptide level compared to those 133 older than ten years (p-value < 0.0001), whereas baseline values did not differ between the 10-134 18 years and >18 years age groups (p-value 0.85). However, the C-peptide change over time was not significantly different between the three age intervals (p-value 0.46). This indicated 135 136 that age is associated with baseline C-peptide values but the decline in C-peptide over time is 137 similar for all age groups. In addition, when investigating the distributions of C-peptide decline 138 rates, children < 10 years old had a significantly different distribution of decline rates than 139 those aged 10-18 years (p-value 0.0072). However, neither 10-18 year and >18 year groups nor 140 the >18 year and < 10 year groups had different distributions (p-values 0.075 and 0.7, 141 respectively) (Supplementary Fig. 2). These findings indicate a degree of association between 142 the rate of decline and age among children, and as a result, age was included after log 143 transformation as a covariate in our models to correct for potential effects on the relationship 144 between C-peptide slopes and 'omics.

- 147 significant association with baseline C-peptide (p-value 0.64) or slope (p-value 0.16).
- 148
- 149
- 150

¹⁴⁶ Evaluating the association of sex with the C-peptide change over time (Fig. 2D) we found no

151 Multi-omics integration analysis

The multi-omics data set overview is shown in Fig. 3A. Missing values, seen predominantly in 152 153 the immunomics data set, are disregarded by MOFA and do not affect the decomposition of 154 the data into latent factors. After training MOFA on the multi-omics data set (Fig. 3B) the latent 155 factors that capture most of the variance across participants were represented by the mRNA 156 and miRNA data. MOFA captures latent factors with common variance across the different 157 data sets, even though certain data types appear to be responsible of most of the captured 158 variance (Factors 1 to 7). This indicates that certain degree of heterogeneity exists across data 159 sets, making the integration more challenging.

160

161 Importantly, however, latent factors 15 and 18 were significantly associated (p-values < 0.1adjusted by Benjamini-Hochberg) with C-peptide slopes (Fig. 3D) but not with age or baseline 162 C-peptide. The amount of variance captured by latent factors 15 and 18 is 2.62% and 1.84%, 163 respectively, indicating that the decline of C-peptide over time is not among the major sources 164 165 of variance across the participants, but is sufficiently strong to be captured by this method. The 166 differences in the strength of associations for latent factors 15 and 18 with the progression groups and C-peptide slopes indicated that latent factor 15 captures a non-linear association 167 168 with the progression groups (Fig. 3C), and for latent factor 18 a linear association with the rate of C-peptide decline (Fig. 3E). As the two factors correlate with C-peptide decline, they may 169 170 contain molecular signatures useful for explaining the differences in disease progression 171 between patients. Therefore, we continued a thorough scrutiny of these factors.

172

173 Differential gene expression analysis

Differentially expressed genes (DEGs) were identified between the different progression 174 175 groups, with batch and age groups used as covariates (Fig. 4). P-values were adjusted for 176 multiple testing using the Benjamini-Hochberg procedure and genes with an adjusted p-value 177 < 0.1 were reported as differentially expressed genes (DEG). Fig. 4 shows the volcano plots of 178 the different comparisons together with the genes belonging to latent factors 15 and 18. A total 179 of 339 DEGs were observed comparing the rapid decline group and the increasing group (Fig. 180 4A, Supplementary Table 7), 33 DEGs between the rapid and slow decline group (Fig. 4B, 181 Supplementary Table 8), and 1,205 DEGs between the slow decline group and the increasing 182 group (Fig. 4C, Supplementary Table 9). Additionally, differential gene expression was 183 performed for the C-peptide slopes, hence studying the linear change in gene expression with

respect to the rate of decline of C-peptide over time. Here we found 484 DEGs (Fig. 4D,Supplementary Table 10).

186

More DEGs were observed when comparing the slow and increasing than between rapid and 187 188 increasing progression groups, with little overlap between the significant top-ranking genes. 189 Additionally, very few genes were differentially expressed between rapid and slow progression 190 groups. Altogether, these results might indicate that even though the rapid and slow progression 191 groups are more alike, the set of DEGs between these two groups and the increasing group are 192 not the same. To further confirm this, two additional differential expression analyses were 193 performed. One between the rapid-slow groups combined versus the increasing group and 194 another between the slow-increasing groups combined versus the rapid. The analyses showed that the rapid-slow vs increasing comparison produced 1,804 DEGs (Supplementary Table 11), 195 196 while the slow-increasing vs rapid comparison produced 18 DEGs (Supplementary Table 12). This indicates that the increasing progression group is much more dissimilar in its blood sample 197 198 expression profile towards the other two groups at the early stage of type 1 diabetes 199 manifestation. Therefore, the underlying biological processes involved in the developing 200 disease progression do not vary much at this early time of the disease manifestation among 201 people experiencing in the future different degrees of loss of β -cell function. At baseline they 202 vary significantly more when comparing people experiencing in the future loss of β -cell 203 function and those experiencing an improvement in β -cell function.

204

205 The similarity between DEGs found by the continuous change in C-peptide levels (n=484) and 206 DEGs between the rapid and increasing group (n=339) showed an overlap of 209 genes. The 207 rapid-slow vs increasing DEGs (n=1,804) had a bigger overlap with the continuous C-peptide 208 levels where 313 of the same DEGs were found. In all cases, the DEGs had the same sign of 209 their log2 fold changes for both analyses. Therefore, most DEGs were observed for the 210 continuous change were also found when investigating progression groups. Nonetheless, we 211 believe that the linear association of blood gene expression at baseline with the C-peptide 212 slopes is more informative regarding the disease progression. We observe that change in β -cell 213 function follows a gradient, so by categorizing participants into groups, we lose the resolution 214 that the C-peptide slopes are providing.

- 215
- 216
- 217

218 Annotation of latent factors

219 To examine the biological pathways in the two most relevant latent factors, we used gene set 220 enrichment analysis. This analysis was divided into genes positively regulated in the rapid decline group and genes negatively regulated in the rapid decline group. Fig. 5 displays the top 221 222 15 significant pathways in each of the two associated latent factors (p-values < 0.1 adjusted by 223 Benjamini-Hochberg). Negatively regulated genes in latent factor 15 are enriched in the 224 immune system and signaling by G protein-coupled receptors (GPCR) pathways. Of specific 225 interest are pathways associated with innate immunity, such as neutrophil degranulation, with 226 high expression of granule proteins (e.g. CTSs, MPO) pointing to the presence of activated or 227 degranulated neutrophils; and platelet activation, signaling and aggregation (the latter not 228 shown). Also, several pathways pointing to cytokine signaling and interleukin (e.g. IL-1 β) 229 signaling emerge. Regarding the role of GPCRs, several pathways are associated with latent 230 factor 15, such as signaling by GPCRs, downstream signaling and GPCR ligand binding. 231 Positively regulated genes in latent factor 15 are also enriched in immune system pathways, 232 with again an important contribution of the innate immune system, although here it seems that 233 the increase is mainly attributed to resting neutrophils, with for instance high expression of 234 LY96. Collectively these data show that GSEA pathways in innate immunity are mainly 235 associated with the activation status of the neutrophils, with shift in the balance of resting 236 neutrophils versus activated or degranulated neutrophils.

237

Negatively regulated genes in latent factor 18 are enriched in influenza infection pathways and mRNA translation pathways, suggesting that viral mRNA replication and translation by host cell machinery are major pathological features of this association. Positively regulated genes in latent factor 18 did not show a particular pattern of enrichment.

242

243 Furthermore, the relation of the latent factors' genes to previous type 1 diabetes publications 244 was studied. Using the Open Targets database¹⁰, a total of 174 genes out of the 668 top genes 245 (three-fold higher than expected by chance) in the latent factor 15 have been previously 246 associated with type 1 diabetes (p-value 0.03). On the other hand, the overlap between the top 247 genes in the latent factor 18 and associated disease genes was not significant. These results 248 indicate that latent factor 15 is capturing a set of genes composed of known disease targets (e.g. 249 INSR, NDUFA4, CTSH) as well as potential new candidate genes already detectable in blood 250 in the early phase of type 1 diabetes.

252 Interpretation of biological networks

253 Biological networks were constructed for latent factors 15 and 18 separately, based on protein-254 protein or protein-protein-miRNA interactions (Supplementary Fig. 3 and 4). As the two network types yielded similar results, we selected the protein-protein-miRNA networks for the 255 256 focus of our interpretations. The latent factor 15 network revealed a diverse set of biological 257 functions (Supplementary Fig. 5), some of them overlapping with the pathways shown in Fig. 258 5. Immune system responses, signaling by different receptors and lipid metabolism are (widely) 259 represented in these clusters. Notably there is an enrichment of lipid metabolism pathways as 260 the lipidomic data also influenced latent factor 15. Some of the genes significantly associated 261 with the C-peptide slopes also appear in several of the clusters, which further validates the 262 biological processes captured by the latent factor. The latent factor 18 network was smaller and 263 had more loosely defined clusters (Supplementary Fig. 6). Nonetheless, it captured a similar set of biological functions compared to the latent factor 15 network. Eukaryotic/viral mRNA 264 265 translation is the main difference between the two networks, which appear as the biggest and 266 more interconnected cluster of the latent factor 18 network. In this case, only one of the genes 267 in this network was significantly associated with the C-peptide slopes.

268

269 Immunomics signature

270 Analysis of immune cell populations identified based on standard markers and their association 271 with the C-peptide slopes revealed that Natural Killer (NK) cells were significantly associated 272 after p-value adjustment, (Fig. 6A), with higher levels of NK cells observed in people with 273 slow disease progression (Fig. 6B). Examination of the relationship between C-peptide slope 274 and NK cell frequency in individual progression groups indicated the strongest correlation was 275 observed among rapid progressors (Fig. 6C). Unsupervised analysis of the immunomics data 276 revealed distinct clusters among the progression groups. Fig. 7A shows a FlowSOM color-277 density map of CD16 expression levels with node sizes representing the frequency of cells in 278 each cluster. Meta-cluster 19 (MC-19) was assigned as the primary NK (CD56loCD16+) subset 279 based on lineage marker expression and was significantly more abundant in the increasing 280 versus rapid progression groups (8.8 vs 6.3% p-value=0.013). Examination of markers of NK 281 cell activation and differentiation (KLRG1, TIGIT, CD38, and CD57) in the different 282 progression groups showed higher expression of KLRG1, in the increasing group but lower 283 levels of CD38.

Comparison of the genes associated with latent factor 15 and the leukocyte gene signature matrix LM22¹¹ revealed an overlap of 52 genes and enrichment in immune cell-specific genes (p-value 0.0001). The genes were representative of the following five main groups, T-cell specific, macrophage M1 specific, monocyte specific, neutrophil specific, and eosinophil specific (Supplementary Fig. 7). In this way, in addition to capturing immune-related pathways, the latent factor 15 broadly represented immune cell-specific genes.

291

292 Other 'omics associations with disease progression

293 The association of factors derived from running MOFA without the transcriptomics data, did 294 not yield any significant associations with the progression groups nor the C-peptide slopes. We 295 can draw two conclusions based on these results. Firstly, the variance of the miRNA and 296 lipidomics captured by latent factor 15 might indicate that these two omics data sets are only 297 informative of the disease progression in combination with transcriptomics. Interestingly, an 298 enrichment on lipid metabolism pathways was apparent among the genes associated with latent 299 factor 15, indicating that these pathways might have an effect of disease progression. This 300 shows how integration of both lipidomics and transcriptomics data aid in discovering 301 enrichment in specific pathways. Similarly, the incorporation of transcriptomics and miRNA 302 data allowed the discovery of enrichment in viral infection pathways.

303

304 Secondly, the main difference between transcriptomics and the other omics data was that it was 305 determined from whole blood. The remaining omics are collected either from serum, plasma, 306 or PBMCs. Even though some analytes may give similar results, samples obtained from the 307 same medium are more easily comparable. Therefore, the disparity between omics that we 308 observe in the latent factors and in the linear association of each omics data set might be caused 309 by the source medium. This could be considered both a drawback and an advantage. On one 310 hand, it is undesirable that this disparity exists because correlated analytes across omics cannot 311 be studied. This makes the data integration challenging as we cannot observe the joint effect 312 of multiple omics nor validate whether the analytes associated with the disease progression in 313 one data type can also be observed in a different one. On the other hand, the heterogeneity 314 across omics can be seen as complementary information. Each omics data set is capturing a 315 different source of variation, thus, providing additional information not captured by the other 316 omics types. Based on the current data, we cannot conclude whether the plasma and serum 317 omics were not associated with the disease progression due to the medium or the analytes 318 themselves.

320 Discussion

In this study, we identified two latent factors associated with β -cell decline. These factors were 321 322 predominantly influenced by transcriptomics, with secondary contributions of miRNA and lipidomics, respectively. Latent factor 15 revealed an enrichment of immune system pathways, 323 324 the most significant being associated with neutrophil degranulation, cytokine signaling, and 325 immunoregulatory interactions between lymphoid and non-lymphoid cells. Moreover, there 326 were multiple pathways associated with GPCR signaling events. More detailed GSEA revealed 327 that disease progression (C-peptide slopes) was associated with an altered balance between 328 resting and activated/degranulated neutrophils. This is in keeping with previous studies that 329 showed a temporary decline in the number of circulating neutrophils in people with newly 330 diagnosed type 1 diabetes, compared to healthy controls, as well as high circulating levels of neutrophil extracellular traps (NETs)¹²⁻¹⁴. The previous detection of neutrophils and NETs in 331 332 the pancreas of deceased subjects affected by type 1 diabetes, and a correlation between 333 circulating neutrophil numbers with C-peptide levels in pre-symptomatic subjects (non-334 diabetic, at-risk) has implicated that activated neutrophils play a pathogenic role in type 1 335 diabetes¹⁵. Our data add significantly to this hypothesis since we show in longitudinal follow-336 up that the neutrophil profile at diagnosis associates with rate of disease progression.

337

Of further interest, GSEA shows platelet activation to be a feature of latent factor 15, linking our findings to the recent demonstration of a role for activated platelets in the formation of platelet-neutrophil aggregates (PNAs), which are increased in the circulation of subjects during the development of type 1 diabetes¹⁶. It is tempting to speculate that activation of GPCR pathways (also associated with latent factor 15) may play a role in these events since it is a response to a variety of stimuli (chemokines, cytokines, complement fragments) and can trigger neutrophil degranulation¹⁷.

345

In contrast, latent factor 18, which was also associated with β -cell decline, is characterized by features of enrichment of viral mRNA translation and subsequent translation by the host cell machinery. There is a considerable body of literature that associates viral infections with early events in type 1 diabetes development as well as peri-diagnosis events¹⁸. As a result, virus infection has often been cited as an autoimmunity-triggering event as well as a diseaseprecipitating event. Our findings in the context of the present study design are entirely consistent with the latter hypothesis, which could be addressed in follow-up viromic studies

targeted to samples in which both the relevant viral mRNA translation signals and negativeslope of C-peptide decline are prominent.

355

356 Molecular and cellular signatures of adaptive immune responses were by and large not 357 observed to be associated with β -cell decline in our study, which might at first sight be 358 considered a surprise, given the strong credentials, at genomic, pathological and mechanistic 359 levels, for type 1 diabetes being the archetype of an organ-specific autoimmune disease. 360 However, it is entirely plausible that the detection of such associations is challenging in whole 361 blood or whole mononuclear cell analyses, both because the disease-relevant, β-cell antigen-362 specific lymphocytes are rare, and even more importantly, because they may be sequestered at 363 inflammatory sites. Certainly, smaller scale studies focused on using appropriately sensitive 364 technologies have identified that the activation and differentiation state of circulating antigen-365 specific cytotoxic T lymphocytes, for example, correlate with changes in β -cell function after the diagnosis of type 1 diabetes⁸. Amongst the lymphocyte studies presented here, our 366 367 observation of a prominent NK cell signal related to rapid β -cell decline is of considerable 368 interest. NK cells have features of both innate and adaptive immune cells and play a key role in anti-viral responses. Both pro-inflammatory and regulatory functions have been ascribed to 369 370 these cells, and functional subtypes can be partially differentiated by surface markers. Previous 371 studies examining the frequency of NK cells in individuals affected by type 1 diabetes have 372 consistently reported lower circulating levels of both proinflammatory and regulatory NK cells when compared to aged-matched non-diabetic subjects^{19,20,10}, potentially reflecting homing to 373 374 inflammatory sites in the pancreas. Consistent with this, we observed lower circulating levels 375 of NK cells (both effector and regulatory subtypes according to surface markers) in the rapid 376 decline group. Of interest, reduced circulating NK cell levels are also associated with viral 377 infection, linking this observation to the viral signatures already described. Future functional 378 studies will be required to explore the pathological implications of these findings, since the 379 immune phenotyping performed here was limited to expression of CD38 (NK cell activation) 380 and KLRG1 (an inhibitory receptor associated with an exhausted phenotype).

381

Key strengths of the study include (i) the setting of a large, longitudinal natural history study conducted across multiple European sites according to standardized clinical and laboratory protocols; (ii) access through the INNODIA network to highly specialized, systems-based technology platforms for parallel multi-parametric analysis; (iii) leverage of new tools in integrated multi-omics factor analysis to discover signatures that are significantly associated

with rate of disease progression for the year following diagnosis. This period of the disease is important since it represents the phase during which disease-modifying immunotherapies are typically trialed for their effect on arresting β -cell decline. Factors identifiable at baseline that associate with faster β -cell decline could be used to conduct shorter and smaller trials (e.g. by enrollment of a rapid-decline group), an important step towards de-risking the investment needed to bring disease modifying strategies into clinical use.

393

394 Finally, we want to highlight specificities of the present study that can be interpreted as 395 limitations or strengths. Our INNODIA natural history collection involves individuals from the 396 ages of one up to 45 years, and thus includes the whole lifespan of people living with type 1 397 diabetes. Although this may render interpretation of findings in this clearly heterogenic disease 398 more complex, it may add to the identification of common factors that drive disease, 399 irrespective of age. We used fasting C-peptide as read-out for β -cell function rather than 400 stimulated C-peptide and could demonstrate similar trends in decline of function using this 401 simple parameter. Although collecting throughout Europe, the population studied is almost 402 completely white Caucasian, thus limiting the generalizability of the findings to a global 403 population, where type 1 diabetes is becoming more prevalent in non-Caucasian people. 404 Confirmation of our observations will therefore be needed in more diverse cohorts. Our work 405 reports on a small cohort of just under 100 people with newly diagnosed disease. However, we 406 demonstrate that even in such small numbers, using deeply phenotyped individuals and 407 standardized operating procedures, application of systems biology techniques can lead to 408 significant associations. Here we believe that the collaboration between academics, 409 foundations, industry and people affected by type 1 diabetes and their families within 410 INNODIA was a unique driver. We created strict protocols for follow up where people could 411 be convinced to participate with support of materials created by the PAC (People with diabetes 412 Advisory Committee), we set up a highly standardized sample collection (e.g. even 413 standardizing the pipet tips for miRNA sample collection) and applied homogeneous 414 laboratory procedures. Importantly, we brought all data into a GDPR-conform centralized 415 database, allowing clean data collection and high quality data for input into the analysis.

416

In summary, the presented study addressed the drivers of disease heterogeneity in type 1 diabetes by leveraging opportunities presented by a highly integrated clinical network featuring embedded research platforms with the capability to generate large systems-level datasets. One

420 of the two factors identified showed correlation to neutrophil degranulation, cytokine signaling,

421 lymphoid and non-lymphoid cell interactions and G-protein coupled receptor signaling events,

422 while the second signature, pathways related to translation and viral infection were inversely

423 associated with change in β -cell function. The derived latent factors were used to identify

424 specific signatures, which were further investigated for biomarker opportunities and

425 mechanistic pathways that correlate with β -cell decline. This shows how multi-omics analysis

426 can be used as an important foundation for the development and testing of disease-modifying

427 therapies in the future.

428 Methods

429 Subjects with type 1 diabetes

430 For this in depth analysis, we included the first 100 subjects with newly diagnosed (<6 weeks) 431 type 1 diabetes enrolled in the INNODIA natural history study. Using a consecutive 432 recruitment approach, subjects were included based on baseline omics data availability, an even 433 gender distribution and biosample availability, positivity for at least one diabetes-related 434 autoantibody (GADA, IA-2A, IAA, ZnT8A), and age between one to 45 years. Two subjects 435 were excluded due to incomplete 'omics datasets and one following the detection of a MODY 436 gene mutation. The final analysis cohort comprised 49 male and 48 female study participants 437 (Table 1), the average age at diabetes diagnosis of 13.2 years (SD 8.5; two-ten years n=38; ten-438 18 years n=41, 18-39 years n=18), mean disease duration of 3.9 weeks (SD 1.5) and at baseline an average total daily insulin dose of 0.51 IU/kg (SD 0.27), HbA1c of 75 mmol/mol (SD 21.3), 439 fasting C-peptide level of 269 pmol/l (IQR 25.7), fasting glucose level of 7.78 mmol/l (IQR 440 2.8) and BMI SDS of 0.327 units (SD 1.1). Fasted C-peptide measurements were made at four 441 442 visits (Fig. 1A). To define the rate of C-peptide decline over time, we utilized linear mixed-443 effect models to fit the log-transformed fasted C-peptide from day of diagnosis to 12 months 444 (Fig. 1B). The model was fitted using subject-level random effects and the rate of C-peptide 445 change over time. Mixed-effect models were fit using the lme4 R package²¹ with an 446 unstructured random effects variance-covariance matrix.

447

Some individuals did not complete all visits. A total of 69 individuals completed the four visits (baseline, three, six, and 12 months), 21 individuals completed three visits, five individuals completed two visits, and two individuals completed only the baseline visit (not necessarily consecutive visits). At each visit HbA1c was measured and stimulated C-peptide response was determined by mixed meal tolerance test (MMTT) from individuals of at least five years of age. The islet autoantibodies GADA, IA-2A, IAA, and ZnT8A were quantified with the use of specific radiobinding assays as described earlier²².

455

456 Targeted serum proteomics by liquid chromatography-mass spectrometry (LC-MS/MS)

457 Targeted proteomics of baseline serum samples from 91 individuals was performed using

458 liquid chromatography with selected reaction monitoring (SRM) mass spectrometry (LC-

459 MS/MS) to measure 195 peptides, representing 98 target proteins and retention time markers.

460 The list of peptides and proteins measured is provided in Supplementary Table 1.

The samples were reduced, digested, and alkylated, then spiked with isotopically labelled synthetic analogues of the targets, as previously described²³. The batchwise analyses of the samples were made with the periodic inclusion of three internal QC reference controls. Skyline software²⁴ was used to both develop the acquisition method and perform primary processing of the data, including peak integration and quality assessment. The un-normalized data was subsequently exported and prepared for batch correction and normalization²⁵.

467

468 Whole blood transcriptomics

469 We performed transcriptome analysis on whole blood samples collected from 92 individuals 470 as well as four reference RNAs (two anonymous donors) used for normalization and assessing 471 batch effects across sample pools. Prior to RNA extraction, frozen whole blood PAXgene samples were thawed at room temperature for 2 hours and subjected to RNA extraction using 472 473 PAXgene Blood miRNA Kit (PreAnalytix/QIAGEN, Cat# 763134). Total RNA, including 474 RNA longer than approximately 18 nucleotides, was purified according to the manufacturer's 475 protocol. Sample concentration was measured with a Nanodrop 2000 spectrophotometer and 476 Qubit Fluorometric Quantitation (Thermo Fisher Scientific).

477 The quality of the samples was ensured with the Experion Automated Electrophoresis System 478 (Bio Rad) and Agilent 2100 Bioanalyzer RNA Pico chip. Library preparation and sequencing 479 were carried out at the Finnish Functional Genomics Centre (FFGC). Before starting library 480 preparation, ERCC Spike-in Mix 1 (Invitrogen P/N 4456739) was added to 100 ng RNA 481 according to the kit's protocol. RNAseq libraries were prepared using the TruSeq stranded 482 mRNA HT kit and protocol # 15031047 (Illumina). The quality and quantity of the amplified 483 libraries were measured using Advanced Analytical Fragment Analyzer (Agilent) and Qubit 484 Fluorometric Quantitation, respectively. Pooled libraries were sequenced on an Illumina 485 NovaSeq 6000 instrument, using 2x50 bp paired-end sequencing. bcl2fastq2 Conversion 486 Software v2.20.0.422 was used to convert base call files into FASTQ files. The quality of the 487 raw sequencing reads was checked using the FastQC tool (v. 0.11.14). The sequencing data 488 preprocessing was carried out using R (v. 3.6.1) and the related Bioconductor module (v. 3.9). 489 The reads were aligned to UCSC hg38 human reference genome (downloaded from Illumina 490 iGenomes site https://support.illumina.com/sequencing/sequencing software/igenome.html) 491 using Rsubread package (v. 1.34.7) and the same package was used to produce the read counts 492 for the RefSeq annotated genes. The gene-wise counts per million (CPM) were generated using 493 the edgeR package (v. 3.26.8).

495 Circulating Small RNAs sequencing

Expression levels of circulating Small RNAs were analyzed from baseline plasma samples of
n=91 subjects on the same sample set adopting two different Next Generation Sequencing
(NGS) approaches: *(i)* probes-based sequencing focused on miRNAs (targeted) through HTG
EdgeSeq miRNA whole transcriptome assay (Supplementary Table 2); *(ii)* Small RNAs
sequencing using the QiaSeq miRNA/small RNA library preparation kit (untargeted).

501 Plasma samples were shipped to HTG Molecular Inc. in order to be analyzed using rigorous 502 standard procedures. The HTG EdgeSeq miRNA whole transcriptome assay method is an RNA 503 extraction free approach that exploits quantitative nuclease protection assay chemistry using 504 sequence-specific nuclease-protection probes (NPPs). This was followed by an NGS step, in 505 order to allow semi-quantitative analysis of a panel of n=2102 targeted miRNAs (including 506 n=13 housekeepings, n=5 negative process controls, n=1 positive process control and n=2083 507 targeted miRNAs) from 15 µL of plasma. HTG EdgeSeq Plasma Lysis buffer was added to 15 508 µL of each plasma sample. Lysed samples were then transferred to a standard 96-well plate. 509 The NPPs were added to the lysed samples followed by the addition of S1 nuclease to digest 510 non-hybridized RNA. The nuclease digestion reaction was then stopped and each processed 511 sample was used as a template for PCR-based library preparation using specifically designed 512 primers (tags), which share common sequences complementary to 5'-end and 3'-end "wing" 513 sequences of the probes and common adapters required for cluster generation on Illumina NGS 514 platform. Libraries were prepared in accordance with HTG standard procedures, HTG EdgeSeq 515 PCR processing, and HTG EdgeSeq AMPure cleanup of Illumina Sequencing Libraries. 516 Libraries concentration was evaluated by the HTG EdgeSeq KAPA Library quantification kit, 517 and each library was normalized and pooled using the HTG EdgeSeq RUO library calculator. 518 Then, pooled libraries were denatured in 2 N NaOH and sequenced (final concentration 4 pM) 519 onto Illumina NextSeq550 platform (High Output kit v.2 cat. FC-404-2005). Data were 520 returned from the sequencer as demultiplexed FASTQ files. The resulting reads (on average 521 79% passing filter, corresponding to a total of 8.33x10⁸ passing filter reads) were aligned 522 referring to miRbase v.20 using HTG Parser software. Raw reads were standardized into CPM 523 and filtered through the "limma Edge R" R Bioconductor package. For the QiaSeq Small RNA sequencing, total RNA extraction was performed from 200 µL of plasma through 524 525 Serum/Plasma Norgen kit (cat. 55000). Small RNA Libraries were prepared using the QiaSeq 526 miRNA library kit (cat. 331505) following the manufacturer's instructions. QiaSeq strategy 527 assigns Unique Molecular Index (UMI) during reverse transcription step to every mature 528 miRNA molecule, in order to enable unbiased and accurate Small RNAome-wide

529 quantification of mature miRNAs and additional small RNAs by NGS. Libraries quality control 530 (QC) was performed by quantifying their concentration through QUBIT 3.0 spectrofluorometer 531 (Qubit[™] dsDNA HS Assay Kit, cat. Q32854) and assessing their quality using capillary electrophoresis in Bioanalyzer 2100 (Agilent High Sensitivity DNA kit cat. 5067-4626). The 532 533 quality of libraries was evaluated considering electropherograms showing a peak comprised 534 between 175 and 185 bp as high quality. Following QC, all libraries were normalized until 2 535 nM and pooled, denatured in 0.2 N NaOH, and further sequenced (final concentration 175 pM) 536 using the Illumina NovaSeq 6000 platform (NovaSeq 6000 SP Reagent Kit (100 cycles) 537 cat. 20027464, NovaSeq XP 2-Lane Kit cat. 20021664, using the XP protocol applying 75x1 538 single reads). Data were returned from the sequencer as demultiplexed FASTQ files. Resulting 539 reads (on average 87% passing filter, corresponding to a total of 1.11×10^9 passing filter reads) were mapped using QIAGEN Gene Globe data analysis center software, which adopts a 540 541 sequential alignment strategy to map to different databases (perfect match to miRbase v.21) 542 mature, miRBase hairpin, noncoding RNA, mRNA and other RNA, and ultimately a second 543 mapping to miRBase mature, where up to two mismatches are tolerated) using bowtie (bowtie-544 bio.sourceforge.net/index.shtml). At each step, only mapped sequences were passed to the next 545 step.

546

547 Plasma Metabolomics (GCxGC-MS)

548 83 metabolites, covering various amino acids, fatty acids and sugars etc. (Supplementary Table 549 3), was generated from baseline plasma samples as described before²⁶. In brief, 30 μ L blood 550 samples from 93 participants were spiked with 10 μ L of the internal standard mixture (d4-551 succinic acid, d5-glutamic acid, d8-valine, and d33-heptadecanoic acid.; Sigma Aldrich). 552 Samples were vortex-mixed and incubated on ice for 30 min and centrifuged (10,000 rpm, 3 553 min, 4°C). Finally, 180 μ L of the filtered extracts were transferred to glass vials and evaporated 554 dry before derivatization.

The samples were derivatized using a previously described procedure²⁷, where reactive groups are converted into trimethysilyl derivates, which increases the volatility of the biomolecules. The polar metabolites were then analyzed using a Pegasus 4D (LECO; Saint Joseph; USA) system, which combines two-dimensional chromatographic separation with time-of-flight (TOF) mass spectrometric detection. Identifications were assigned using the National Institute of Standards (NIST) database and Steno Diabetes Center Copenhagen in-house libraries. After data acquisition, the raw data were pre-processed into a peak table with ChromaTOF (LECO;

562 Saint Joseph; USA). Finally, data were post-processed in R by batch correction, truncation of 563 outliers, and imputation of missing values.

564

565 Plasma Lipidomics (LC-MS)

566 The lipidome (Supplementary Table 4) was measured from baseline plasma samples of 94 567 individuals and two unrelated control samples in four replicates following lipid extraction from 568 a 10 μ L plasma sample using a chloroform:methanol (2:2 V/V) lipid extraction method²⁸. Nine 569 stable isotope labelled and non-physiological lipid species were spiked as internal standards. 570 (Supplementary Table 5).

571 Samples were analysed in positive and negative ion modes of ultra-high-performance liquid-572 chromatography mass-spectrometry (UHPLC-MS; Agilent Technologies; Santa Clara, CA, 573 USA) at Steno Diabetes Center Copenhagen as described previously²⁹⁻³⁰. After data 574 acquisition, the raw data were pre-processed into a peak table with MZmine 2. Finally, data 575 were post-processed in R by denoising as normalization to internal standards, batch correction, 576 truncation of outliers, and imputation of missing values.

577

578 Nine stable isotope labelled and non-physiological lipid species were spiked as internal579 standards (Supplementary data table 2).

- 580
- 581

582 PBMC (cryopreserved) multi-dimensional flow cytometry (Multi-FACS) immunomics

The immunome was examined using cryopreserved peripheral blood mononuclear cells (PBMCs; that were freshly isolated and cryopreserved in Cryostor) from 76 baseline blood samples (Na-heparin) shipped in liquid nitrogen and processed at a single site by Multi-FACS. 36-marker Multi-FACS Cytek Aurora panel (plus one viability dye) was set up and a specific flow gating strategy that allowed enumeration of 150 cell populations was applied (Supplementary Table 6).

All flow data were also analyzed by OMIQ platform (www.omiq.ai), including unbiased clustering (FlowSOM) and dimensionality reduction (UMAP). In FlowSOM analysis, the median intensity of 36 markers were used to generate 100 nodes, which were further clusters as meta-cluster (k=30, grey area on FlowSOM map under randomized speed and Euclidean distancing metric). FlowSOM map provides a concise representation of the number of cell types and visualization of the differential marker profiles by color-density.

596 Samples were processed in five batches (between 12 to 16 samples per batch, consisting of a 597 mixture of samples from each of the five INNODIA immune laboratories) together with two 598 unrelated control samples in each batch using one 2.5x10⁶ PBMCs per sample except for two 599 samples where two aliquots were used due to poor percentage of recovery (range from 11.2 to 600 228.8%, average of 68.1%). Viability assessed by trypan blue ranged between 70 and 100% (average 94%). An average of 1.51x10⁶ (range 0.54-2.8x10⁶) cells were used for staining. List 601 602 of Multi-FACS flow panel antibodies and reagents used is detailed in Supplementary data table 603 3. PBMCs were first stained using Live/dead blue for 15 min at room temperature, washed with 604 FACS buffer (PBS with 0.2% BSA and 2mM EDTA), and incubated with Fc receptor blocker (TruStain FcX Fc; BioLegend) for 10 min at room temperature. Without wash, samples were 605 606 stained in a 37°C waterbath for 15 min using mastermix 1 (containing antibodies against 607 CXCR3. CD117, CD294/CRTH2, and CD161). Samples were further stained in waterbath for 608 15 min using mastermix 2 (containing antibodies against CXCR5, ICOS, CCR7, and CCR6), 609 followed by 30 min at room temperature using mastermix 3 (Supplementary data table 3). 610 Finally, samples were washed using FACS buffer, then fixed and resuspended in PBS 611 containing 1% paraformaldehyde (Alfa Aesar). Single colour controls were made using PBMC 612 for all colours except for CD294, CD117, CD161, and TCRgd where BD mouse or rat comp 613 beads were used instead due to low cell expression. Single colour controls were subjected to the same buffer and fixed as the multi-colour stained samples. SpectroFlo QC beads were run 614 615 daily and single colour controls were acquired in the reference library, which was subsequently 616 used for live unmixing during sample acquisition on a Cytek Aurora cytometer. Flow data were 617 analysed using FlowJo software (an example of the gating strategy is shown in Supplementary 618 Fig. 8 and checked by an independent reviewer).

619

620 Multi-omics data pre-processing, integration, and analysis

621 For transcriptomics and miRNA data, the DESeq 2 package³¹ was used to normalize the counts 622 using the variance stabilizing transformation (VST). The transcriptomics and miRNA data sets 623 were filtered for low counts (features with less than 10 counts in total or features with zero 624 counts in more than 90% of the samples). The proteomics, metabolomics, lipidomics and 625 immunomics data sets were log2 transformed. The transcriptomics, proteomics, and 626 immunomics data were corrected for batch effects associated with dataset-specific factors 627 (sequencing at different days or different handling of the samples) using the limma package in 628 R. Finally, all the data sets were corrected for age. The age was log-transformed to account for 629 the growth effect in children (one year difference in adults is not equivalent to one year

difference in children). This was necessary due to the high degree of age heterogeneity presentin the cohort and the association of the fasted C-Peptide slopes with age.

632

633 The omics data sets were integrated using the general framework in the Multi-Omics Factor 634 Analysis (MOFA) package from 2018³². MOFA performs a dimensionality reduction of the omics data into a lower-dimensional latent space (Fig. 1C). The latent factors generated by 635 636 MOFA capture sources of global variability across the different omics data sets. Each factor 637 has an underlying weight for every feature, which can be used to annotate the factors in terms 638 of omics features, yielding a specific molecular signature for each factor. MOFA was run with 639 default parameters and 20 latent factors. The model was initialized with different random seeds 640 yielding similar results, generally only altering the number assigned to each factor associated 641 with the C-peptide slopes.

642

Latent factors were associated with the C-peptide slopes using the Spearman correlation. Other covariates were also analyzed such as age at baseline and C-peptide at baseline. The association of the latent factors with the progression groups was calculated using the Kruskal-Wallis test and each group was compared using a Mann-Whitney U test.

647

Gene Set Enrichment Analysis (GSEA)³³ was performed in order to better characterize the 648 649 genes with the largest weight in the latent factors. This analysis was performed using the 650 MOFA GSEA function that utilizes a modified version of the principal component gene set enrichment scheme (PCGSE)³⁴. The Reactome database was the gene set annotation used for 651 652 this analysis. The GSEA was performed separately for genes with a positive and negative 653 weight in each latent factor. This was done to avoid combining genes that are upregulated 654 (positive weight) and downregulated (negative weight) in the latent factor, as these two groups 655 of genes might be involved in different biological pathways. The top 15 significant pathways 656 for each latent factor (positive and negative weights) were selected and grouped by biological 657 pathway.

658

Differential gene expression of individual genes was determined with the DESeq 2 package³¹. Models included covariates for the batch variable (different runs) and the age of the people. Age was encoded as a categorical variable defined in three groups, less than ten years, between ten and 18 years, and more than 18 years. Differential gene expression was assessed between rapid and slow groups, rapid and increasing and slow and increasing, respectively.

664

For biological network analysis, two types of interaction networks were constructed. One was 665 compiled from the STRING³⁵ database to study protein-protein interactions or associations 666 only. Another network was compiled from the mirTarBase³⁶ (miRNA-gene), which was 667 668 combined with the STRING network to study protein-protein-miRNA interactions or associations. The STRING database was filtered for high-confidence interactions (combined 669 670 score above 0.7) and miRNA-gene interactions had to be reported by at least two publications 671 and two non-high-throughput methods. We decided to focus on genes and miRNAs only 672 because those were the omics types with higher weights in the most relevant latent factors.

673

674 The association between the biological networks and the latent factors was performed using 675 the PCSF graph optimization approach. This method allows us to interpret the biological 676 landscape of the interaction network based on the importance/weight of each gene/miRNA in 677 the latent factor. The output is a subnetwork that captures interactions between the 678 genes/miRNAs with a higher importance in the latent factor. In order to select a subset of genes 679 and miRNAs to construct the network, only genes with normalized absolute weights three-fold 680 higher than expected by chance and miRNAs with normalized absolute weights two-fold higher 681 than expected by chance were selected. Grid-search was performed to select the best 682 parameters based on the network that had a high number of genes/miRNA from the latent factor 683 while keeping number of genes/miRNA not observed in the latent factor low 684 (μ =0.005, ω =1, β =5000). The final network was constructed using 20 runs with noise to edge 685 costs (r=0.1) that were combined and clustered using the edge-betweenness algorithm. Gene 686 set enrichment analysis was performed on the clusters obtained from the network.

687 Figures

688

689 Fig. 1. Cohort data and analysis overview. A) The cohort consists of 97 people with newly 690 diagnosed type 1 diabetes. Multi-omics data were collected at baseline (within six weeks after 691 diagnosis of type 1 diabetes) and clinical data were collected at baseline and at three, six, and 692 12 months. B) Participants were divided into three groups based on their change of insulin 693 secretion levels (fasted C-peptide measurements) from baseline to 12 months. C) Multi-694 Omics Factor Analysis was performed to obtain an integrated signature across omics data 695 types followed by differential expression analysis for each omics data type independently. 696 697 Fig. 2: Fasted C-peptide trends over time. Time is represented as days from type 1 diabetes diagnosis. A) C-peptide values over time for all participants. B) C-peptide values over time 698 699 divided into progression groups (progression terciles). C) C-peptide values over time for

700 different age groups. D) C-peptide values over time for males and females, respectively.

701

702 Fig. 3. A) Overview of the multi-omics data sets, describing the number of features per data 703 set and the level of missing data (white). B) Latent factors obtained from MOFA, the color 704 scale represents the variance captured by each of the latent factors indicating the level of 705 integration of the data types for each factor. C) Association of latent factors 15 and 18 values 706 with the different progression groups. D) Spearman correlation of latent factors with the 707 fasted C-peptide slopes, baseline fasted C-Peptide, Age (log scale), and BMI-SDS. P-values 708 were adjusted by Benjamini-Hochberg. E) Spearman correlation of fasted C-peptide slopes 709 against latent factor values (15 and 18).

710

Fig. 4. Volcano plot of differential gene expression between progression groups. The color
indicates gene membership to either or both associated latent factors. A) DGE between rapid
and increasing progression groups (339 genes are differentially expressed). B) DGE between
rapid and slow progression groups (33 genes are differentially expressed). C) DGE between
slow and increasing progression groups (1,206 genes are differentially expressed). D) DGE
for C-peptide slopes (484 genes are differentially expressed).

Fig. 5. GSEA was performed separately for genes with positive weights in the latent factor
(upregulated in rapid decline) and genes with negative weights in the latent factor

- 720 (downregulated in rapid decline). Pathways are coloured depending on the main pathway
- they belong to, according to Reactome. P-values were adjusted using Benjamini-Hochberg.
- 722
- 723 Fig. 6. Immunomics association with C-peptide slopes. A) Benjamini-Hochberg adjusted p-
- value for the linear association of immune cells abundances with the C-peptide slopes
- 725 (correcting for batch effects and age groups). B) NK cell levels for the different progression
- 726 groups (as a frequency of total live mononuclear cells). C) Spearman correlation of fasted C-
- 727 peptide slopes versus NK cell frequency for the different progression groups. D) FlowSOM
- unbiased cluster analysis on live CD45⁺ PBMCs of Donor D07 (Increasing, left) and K40
- 729 (Rapid, right) highlighting Metacluster-19 (red-circle) as a primary NK (CD56^{lo}CD16⁺)
- rd subset. Colour-density and circle size were overlaid as CD16 intensity and number of events,
- respectively. E) Bar charts representing NK marker expression on the selected clusters in
- each progression group.

734 Tables

Table 1. Clinical and demographic data for the type 1 diabetes cohort across progression

736 groups. P-values were calculated using the Kruskal-Wallis test.

	Rapid (N=33)	Slow (N=32)	Increasing (N=32)	P-value	Overall (N=97)
Sex					
Female	20 (60.6%)	15 (46.9%)	13 (40.6%)	0.256	48 (49.5%)
Male	13 (39.4%)	17 (53.1%)	19 (59.4%)		49 (50.5%)
Age (years)					
Mean (SD)	11.2 (9.17)	12.9 (7.94)	15.6 (7.94)	0.0125	13.2 (8.49)
Median (IQR) [Min, Max]	9.60 (8.97) [2.01, 38.1]	10.9 (8.68) [2.08, 36.4]	13.4 (5.23) [7.57, 38.8]		11.8 (8.08) [2.01, 38.8]
Age Intervals					
<10	17 (51.5%)	14 (43.8%)	7 (21.9%)	0.16	38 (39.2%)
>10-18	11 (33.3%)	12 (37.5%)	18 (56.3%)		41 (42.3%)
>18	5 (15.2%)	6 (18.8%)	7 (21.9%)		18 (18.6%)
Disease duration (weeks)					
Mean (SD)	3.88 (1.52)	3.80 (1.66)	4.10 (1.43)	0.843	3.93 (1.53)
Median (IQR) [Min, Max]	4.40 (2.50) [0.900, 6.40]	4.35 (2.35) [0.900, 6.30]	4.40 (1.70) [0.700, 6.10]		4.40 (2.20) [0.700, 6.40]
BMI SDS					
Mean (SD)	0.0719 (1.05)	0.397 (1.02)	0.511 (1.20)	0.153	0.327 (1.10)
Median (IQR) [Min, Max]	0.0800 (1.19) [- 2.32, 2.47]	0.350 (1.60) [- 1.56, 2.72]	0.610 (1.35) [- 2.00, 2.28]		0.260 (1.57) [- 2.32, 2.72]
Missing	1 (3.0%)	0 (0%)	0 (0%)		1 (1.0%)
Glucose (mmol/l)					
Mean (SD)	8.43 (5.57)	8.42 (5.33)	6.45 (2.20)	0.22	7.78 (4.69)
Median (IQR) [Min, Max]	7.10 (2.70) [3.70, 31.5]	6.70 (2.93) [3.60, 26.9]	6.10 (2.25) [3.70, 13.8]		6.40 (2.80) [3.60, 31.5]
Insulin dose (IU/kg)					
Mean (SD)	0.544 (0.279)	0.498 (0.247)	0.498 (0.281)	0.819	0.514 (0.268)
Median (IQR) [Min, Max]	0.545 (0.291) [0.136, 1.46]	0.468 (0.243) [0.108, 1.20]	0.500 (0.429) [0.0359, 1.01]		0.500 (0.354) [0.0359, 1.46]
Missing	1 (3.0%)	1 (3.1%)	0 (0%)		2 (2.1%)

t is made available under a CC	-BY 4.0 International license.
--------------------------------	--------------------------------

HbA1c (mmol/mol)					
Mean (SD)	72.2 (21.4)	74.9 (24.2)	78.0 (18.1)	0.699	75.0 (21.3)
Median (IQR) [Min, Max]	75.0 (27.3) [8.70, 119]	73.0 (29.5) [13.4, 130]	80.3 (22.4) [50.0, 130]		77.5 (25.7) [8.70, 130]
Missing	1 (3.0%)	1 (3.1%)	1 (3.1%)		3 (3.1%)
Baseline C- peptide (pmol/l)					
Mean (SD)	235 (183)	248 (185)	324 (263)	0.296	269 (215)
Median (IQR) [Min, Max]	165 (228) [26.1, 809]	240 (204) [15.0, 986]	264 (268) [25.8, 1290]		224 (239) [15.0, 1290]
12 Month C- peptide (pmol/l)					
Mean (SD)	64.7 (59.8)	194 (137)	432 (206)	< 0.001	234 (214)
Median (IQR) [Min, Max]	41.6 (83.5) [11.7, 222]	161 (136) [45.8, 635]	433 (246) [96.7, 896]		163 (283) [11.7, 896]
Missing	7 (21.2%)	9 (28.1%)	5 (15.6%)		21 (21.6%)
GADA					
Negative	5 (15.2%)	11 (34.4%)	8 (25.0%)	0.199	24 (24.7%)
Positive	28 (84.8%)	21 (65.6%)	24 (75.0%)		73 (75.3%)
IA-2A					
Negative	9 (27.3%)	12 (37.5%)	9 (28.1%)	0.615	30 (30.9%)
Positive	24 (72.7%)	20 (62.5%)	23 (71.9%)		67 (69.1%)
IAA					
Negative	4 (12.1%)	10 (31.3%)	10 (31.3%)	0.118	24 (24.7%)
Positive	29 (87.9%)	22 (68.8%)	22 (68.8%)		73 (75.3%)
ZnT8A					
Negative	12 (36.4%)	10 (31.3%)	14 (43.8%)	0.582	36 (37.1%)
Positive	21 (63.6%)	22 (68.8%)	18 (56.3%)		61 (62.9%)
Detectable autoantibodies					
Mean (SD)	3.09 (0.947)	2.66 (0.902)	2.72 (0.851)	0.0961	2.82 (0.913)
Median (IQR) [Min, Max]	3.00 (2.00) [1.00, 4.00]	3.00 (1.00) [1.00, 4.00]	3.00 (1.00) [1.00, 4.00]		3.00 (2.00) [1.00, 4.00]

741 742	Other
743	Data Availability
744	The data generated and analysed is person-sensitive as it can be used to identify people based
745	on their sequence variation and can be accessed in secure environments only. Access to data
746	can be provided by application to the INNODIA Data Access Committee by emailing
747	Professor Lut Overbergh (lutgart.overbergh@kuleuven.be). Processed results of GSEA
748	analysis is available as supplementary material.
749	
750	Code Availability
751	The primary software used for this work was Multi-Omics Factor Analysis (MOFA). The
752	code for this software is available at <u>https://github.com/bioFAM/MOFA2</u> .
753	
754	Ethics Declaration
755	The INNODIA study protocol was approved by the London - City & East Research Ethics
756	Committee on 28 October 2016 (REC 16/LO/1750) IRAS Project ID 210497. Subsequently,
757	after translation of the participants' documentation, approval was obtained from local Ethic
758	authorities throughout the entire INNODIA clinical network.
759	
760	Acknowledgments
761	We gratefully acknowledge all participants of the INNODIA natural history study which built
762	the basis for the work presented here. Without the outstanding engagement of the people with
763	type diabetes and their relatives and friends participating in the INNODIA clinical efforts,
764	this data and new knowledge gain would not have been possible. The authors also want to
765	thank all the clinical personnel for their dedication in the participant recruitment,
766	characterization, sample collection and preparation that was at the basis of this analysis. We

dedicate this work to the late Professor David Dunger, who inspired INNODIA and lay at thebasis of this analysis.

769

JJAA, CB, SFAB, DBD, PJC, MK, AMS, GS, LLE, FD, TT, RL, LO, CM, MP, SB designed
the study. JJAA, CB, KB, RM, NA-S, IM, CL-Q, TS, JHL, GEG, MKH, TS, OR, PJC, JHL,
GS, TT collected data and performed analyses. JJAA, CHJ, TT, LO, CM, MP, SB wrote the
manuscript. All authors revised the manuscript for crucial content and approved the final
version. All authors had full access to all the data and had final responsibility for the decision
to submit for publication. A complete list of the partners of the INNODIA consortium is
included separately.

778

779 Declaration of interests

780 CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and

781 Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche,

782 Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres,

783 Mannkind, Sandoz and Vertex. Financial compensation for these activities has been received

by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse,

785 Novo Nordisk, Sanofi and ActoBio Therapeutics; CM serves or has served on the speakers

786 bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Astra

787 Zeneca and Novartis. Financial compensation for these activities has been received by KU

788 Leuven.

789 S.Br. reports having received funding from INNODIA (grant agreement No 115797), having

790 ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S,

791 ALK A/S and managing board memberships in Proscion A/S and Intomics A/S.

792 MK reports ownership and managing board membership in Vactech Oy.

793 CLQ reports serving on advisory boards of Fondation Alzheimer's and Institute Pasteur, and

an affiliation with Novo Nordisk.

⁷⁷⁰ Author contributions

795 LO reports having received funding from INNODIA and INNODIA Harvest.

796

- 797 Supplementary information
- 798 Supplementary information is available for this paper as an appendix.

800 References

- 801 1. Warshauer, J.T., Bluestone, J.A., Anderson, M.S., 2020. New frontiers in the 802 treatment of Type 1 diabetes. Cell Metab. 31, 46-61. 803 https://doi.org/10.1016/j.cmet.2019.11.017 804 2. IDF, D.A., 2021. International Diabetes Federation. (No. 10th edn). Brussels, 805 Belgium. 806 3. Miller, R.G., Orchard, T.J., 2020. Understanding Metabolic Memory: A Tale of Two 807 Studies. Diabetes 69, 291–299. https://doi.org/10.2337/db19-0514 808 4. Rawshani, Araz, Sattar, N., Franzén, S., Rawshani, Aidin, Hattersley, A.T., Svensson, 809 A.-M., Eliasson, B., Gudbjörnsdottir, S., 2018. Excess mortality and cardiovascular 810 disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, 811 register-based cohort study. Lancet Lond. Engl. 392, 477-486. 812 https://doi.org/10.1016/S0140-6736(18)31506-X 813 5. Tatovic D, Dayan CM. Replacing insulin with immunotherapy: Time for a paradigm 814 change in Type 1 diabetes. Diabet Med. 2021 Dec;38(12):e14696. doi: 815 10.1111/dme.14696. 816 6. Battaglia, M., Ahmed, S., Anderson, M.S., Atkinson, M.A., Becker, D., Bingley, P.J., 817 Bosi, E., Brusko, T.M., DiMeglio, L.A., Evans-Molina, C., Gitelman, S.E., 818 Greenbaum, C.J., Gottlieb, P.A., Herold, K.C., Hessner, M.J., Knip, M., Jacobsen, L., 819 Krischer, J.P., Long, S.A., Lundgren, M., McKinney, E.F., Morgan, N.G., Oram, 820 R.A., Pastinen, T., Peters, M.C., Petrelli, A., Qian, X., Redondo, M.J., Roep, B.O., 821 Schatz, D., Skibinski, D., Peakman, M., 2020. Introducing the Endotype Concept to 822 Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care 823 43, 5-12. https://doi.org/10.2337/dc19-0880 824 7. Speake, C., Skinner, S.O., Berel, D., Whalen, E., Dufort, M.J., Young, W.C., 825 Odegard, J.M., Pesenacker, A.M., Gorus, F.K., James, E.A., Levings, M.K., Linsley, 826 P.S., Akirav, E.M., Pugliese, A., Hessner, M.J., Nepom, G.T., Gottardo, R., Long, 827 S.A., 2019. A composite immune signature parallels disease progression across T1D 828 subjects. JCI Insight 4. https://doi.org/10.1172/jci.insight.126917 829 8. Yeo, L., Woodwyk, A., Sood, S., Lorenc, A., Eichmann, M., Pujol-Autonell, I., 830 Melchiotti, R., Skowera, A., Fidanis, E., Dolton, G.M., Tungatt, K., Sewell, A.K., 831 Heck, S., Saxena, A., Beam, C.A., Peakman, M., 2018. Autoreactive T effector 832 memory differentiation mirrors β cell function in type 1 diabetes. J. Clin. Invest. 128, 833 3460-3474. https://doi.org/10.1172/JCI120555 834 9. Dunger DB, Bruggraber SFA, Mander AP, Marcovecchio ML, Tree T, Chmura PJ, 835 Knip M, Schulte AM, Mathieu C; INNODIA consortium. INNODIA Master Protocol 836 for the evaluation of investigational medicinal products in children, adolescents and 837 adults with newly diagnosed type 1 diabetes. Trials. 2022 May 18;23(1):414. doi: 838 10.1186/s13063-022-06259-z. 839 10. Oras A, Peet A, Giese T, Tillmann V, Uibo R. A study of 51 subtypes of peripheral 840 blood immune cells in newly diagnosed young type 1 diabetes patients. Clin Exp 841 Immunol. 2019 Oct;198(1):57-70. doi: 10.1111/cei.13332. 842 11. Chen, B., Khodadoust, M.S., Liu, C.L., Newman, A.M., Alizadeh, A.A., 2018. 843 Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 844 Clifton NJ 1711, 243–259. https://doi.org/10.1007/978-1-4939-7493-1 12 845 12. Harsunen MH, Puff R, D'Orlando O, Giannopoulou E, Lachmann L, Beyerlein A, von 846 Meyer A, Ziegler AG. Reduced blood leukocyte and neutrophil numbers in the 847 pathogenesis of type 1 diabetes. Horm Metab Res. 2013 Jun;45(6):467-70. doi: 848
 - 10.1055/s-0032-1331226.

849	13.	Valle A. Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani
850	10.	G Masini M Maugeri N Porretti L Bonfanti R Meschi F De Pellegrin M Lesma A
851		Rossini S Piemonti I Marchetti P Dotta E Rosi E Battaglia M Reduction of
852		airculating neutraphils proceedes and accompanies type 1 diabates. Diabates 2012
853		$L_{\rm me}(2)(\ell_{\rm c}) 2072 \ 7 \ d_{\rm c}$, 10 2227/4b12 1245
854	1 /	Jun; 02(0): 2072-7. doi: 10.2557/d012-1545.
855	14.	wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, Bornstein SR, Zhou Z, Lam KS, Xu
856		A. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely
850		associated with β -cell autoimmunity in patients with type 1 diabetes. Diabetes. 2014
837		Dec;63(12):4239-48. doi: 10.2337/db14-0480.
858	15.	Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM,
859		Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L,
860		Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K,
861		Sebastiani G, Dotta F, Bosi E; DRI Biorepository Group; Type 1 Diabetes TrialNet
862		Study Group, Battaglia M. Abnormal neutrophil signature in the blood and pancreas
863		of presymptomatic and symptomatic type 1 diabetes. JCI Insight, 2018 Sep
864		20:3(18):e122146. doi: 10.1172/ici.insight.122146.
865	16	Popp SK Vecchio F Brown DI Fukuda R Suzuki Y Takeda Y Wakamatsu R
866	10.	Sarma MA Garrett I Giovenzana A Bosi E Lafferty AR Brown KI Gardiner FE
867		Coupland I A Thomas HE Chong DH Darish CD Dattaglia M Datralli A
868		Simoonovia CL Circulating platelet neutrophil aggregates characterize the
869		Simeonovic CJ. Circulating platelet-neutrophil aggregates characterize the
870		development of type 1 diabetes in humans and NOD mice. JCI Insigni. 2022 Jan $25.7(2)$, 152002, 1 \div 10.1172/ \div \div 14.152002
871	1.7	25;/(2):e153993. doi: 10.11/2/jci.insignt.153993.
872	17.	Othman A, Sekheri M, Filep JG. Roles of neutrophil granule proteins in orchestrating
872		inflammation and immunity. FEBS J. 2021 Mar 8. doi: 10.1111/febs.15803.
073 974	18.	Vehik K, Lynch KF, Wong MC, Tian X, Ross MC, Gibbs RA, Ajami NJ, Petrosino
0/4		JF, Rewers M, Toppari J, Ziegler AG, She JX, Lernmark A, Akolkar B, Hagopian
873		WA, Schatz DA, Krischer JP, Hyöty H, Lloyd RE; TEDDY Study Group. Prospective
8/6		virome analyses in young children at increased genetic risk for type 1 diabetes. Nat
8//		Med. 2019 Dec;25(12):1865-1872. doi: 10.1038/s41591-019-0667-0.
878	19.	Wilson RG, Anderson J, Shenton BK, White MD, Taylor RM, Proud G. Natural killer
879		cells in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1986 Jul
880		26;293(6541):244. doi: 10.1136/bmj.293.6541.244.
881	20.	Fitas AL, Martins C, Borrego LM, Lopes L, Jörns A, Lenzen S, Limbert C. Immune
882		cell and cytokine patterns in children with type 1 diabetes mellitus undergoing a
883		remission phase: A longitudinal study. Pediatr Diabetes. 2018 Aug: 19(5):963-971.
884		doi: 10.1111/nedi 12671
885	21	Bates D Mächler M Bolker B Walker S 2015 Fitting Linear Mixed-Effects
886	41.	Models Using Imed I Stat Softw 67 1-48 https://doi.org/10.18637/iss.v067.j01
887	$\gamma\gamma$	Knin M. Virtanen S.M. Sennä K. Ilonen I. Savilahti F. Vaarala O. Beunanen
888		A Toromo K Hömölöinon A M Doronon I Dosoh H M Holaulinon T
889		A., Icianio, K., Hamalanich, AW., Fatolich, J., Dosch, HW., Hakumen, I.,
890		Akerolom, H.K., Finnish TRIGR Sludy Group, 2010. Dielary intervention in infancy
891		and later signs of beta-cell autoimmunity. N. Engl. J. Med. 363 , $1900-1908$.
001	•••	https://doi.org/10.1056/NEJMoa1004809
892	23.	Bnosale, S.D., Moulder, R., Kouvonen, P., Lahesmaa, R., Goodlett, D.R., 2017. Mass
893		Spectrometry-Based Serum Proteomics for Biomarker Discovery and Validation.
894		Methods Mol. Biol. Clifton NJ 1619, 451–466. <u>https://doi.org/10.1007/978-1-4939-</u>
895		<u>7057-5_31</u>
896	24.	MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen,
897		B., Kern, R., Tabb, D.L., Liebler, D.C., MacCoss, M.J., 2010. Skyline: an open source

medRxiv preprint doi: https://doi.org/10.1101/2023.03.22.23287261; this version posted March 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity	•
It is made available under a CC-BY	4.0 International license .

898 899		document editor for creating and analyzing targeted proteomics experiments. Bioinforma Oxf Engl 26 966–968 https://doi.org/10.1093/bioinformatics/btq054
900	25.	Bates, D., Mächler, M., Bolker, B., Walker, S., 2015. Fitting Linear Mixed-Effects
901		Models Using lme4. J. Stat. Softw. 67, 1–48. <u>https://doi.org/10.18637/jss.v067.i01</u>
902	26.	Orešič M, Anderson G, Mattila I, Manoucheri M, Soininen H, Hyötyläinen T,
903		Basignani C. Targeted Serum Metabolite Profiling Identifies Metabolic Signatures in
904		Patients with Alzheimer's Disease, Normal Pressure Hydrocephalus and Brain Tumor.
905		Front Neurosci. 2018 Jan 9;11:747. doi: 10.3389/fnins.2017.00747. PMID: 29375291;
007	27	PMCID: PMC5/6/2/1.
907	27.	Gika, H.G., Theodoridis, G.A., Plumb, R.S., Wilson, I.D., 2014. Current practice of
908		Pharm Diamad Anal Daviay Dapars on Dharmacoutical and Diamadical Analysis
909		2013 87 12 25 https://doi.org/10.1016/j.jpha.2013.06.032
911	28	Folch J Lees M Sloane Stanley G H 1957 A simple method for the isolation and
912	20.	nurification of total lipides from animal tissues I Biol Chem 226 497–509
913	29.	O'Gorman, A., Suvitaival, T., Ahonen, L., Cannon, M., Zammit, S., Lewis, G.,
914		Roche, H.M., Mattila, I., Hyotylainen, T., Oresic, M., Brennan, L., Cotter, D.R., 2017.
915		Identification of a plasma signature of psychotic disorder in children and adolescents
916		from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. Transl.
917		Psychiatry 7, e1240. https://doi.org/10.1038/tp.2017.211
918	30.	Tofte, N., Suvitaival, T., Ahonen, L., Winther, S.A., Theilade, S., Frimodt-Møller, M.,
919		Ahluwalia, T.S., Rossing, P., 2019. Lipidomic analysis reveals sphingomyelin and
920		phosphatidylcholine species associated with renal impairment and all-cause mortality
921		in type 1 diabetes. Sci. Rep. 9, 16398. https://doi.org/10.1038/s41598-019-52916-w
923	31.	Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and
924		dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
925	22	<u>Arcalaguat B. Valtan B. Arnal D. Districh S. Zanz T. Mariani I.C. Duattran</u>
926	52.	F Huber W Steele O 2018 Multi Omics Factor Analysis a framework for
927		unsupervised integration of multi-omics data sets Mol Syst Biol 14:e8124
928		https://doi.org/10.15252/msb.20178124
929	33.	Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette,
930		M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., 2005.
931		Gene set enrichment analysis: A knowledge-based approach for interpreting genome-
932		wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545-15550.
933		https://doi.org/10.1073/pnas.0506580102
934	34.	Frost, H.R., Li, Z., Moore, J.H., 2015. Principal component gene set enrichment
935		(PCGSE). BioData Min. 8, 25. https://doi.org/10.1186/s13040-015-0059-z
936	35.	Szklarczyk, D., Gable, A.L., Nastou, K.C., Lyon, D., Kirsch, R., Pyysalo, S.,
937		Doncheva, N.T., Legeay, M., Fang, T., Bork, P., Jensen, L.J., von Mering, C., 2021.
938		The STRING database in 2021: customizable protein-protein networks, and functional
939		characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 49,
940 041	26	$\frac{1}{1000} - \frac{1}{1000} \frac{1}{1000} \frac{1}{1000} \frac{1}{10000} \frac{1}{10000000000000000000000000000000000$
941 042	30.	Diabetes Investig 7 652 663 https://doi.org/10.1111//di.12460
942 943		Diabetes mycsug. 7, 052–005. <u>mps.//doi.org/10.1111/jdi.12409</u>
944		
~ ! !		

Cohort data collection









С



Pathways

- log₁₀ adj. p.value

Factor 15

Positive

Category

Factor 18

Positive

Cell Cycle

Immune System

Influenza Infection

Others

Signaling by GPCR

Translation

